Open $183.90
Day Range 182.21 - 189.00
52 Week Range 46.13 - 189.26
Market Cap $71.56B
Shares Outstanding 400.18M
Public Float 338.49M
Beta 0.27
Rev. per Employee $618.00K
P/E Ratio N/A
EPS -$1.94
Yield N/A
Dividend N/A
Ex-Dividend Date N/A
Short Interest 11.84M 04/15/21
% of Float Shorted 3.50%
Average Volume 9.63M

5 Day	1.42%
1 Month	39.31%
3 Month	17.30%
YTD	78.06%
1 Year	277.02%

Sell
Under
Hold
Over
Buy

Number of Ratings 17 Full Ratings

MarketWatch
Dow Jones

Moderna to boost COVID-19 vaccine production at Massachusetts site by 50%

May. 4, 2021 at 8:28 a.m. ET by Jaimy Lee

Moderna expects expanded site to be ready by late 2021, early 2022

May. 4, 2021 at 8:11 a.m. ET by Ciara Linnane

Moderna says expansion will support 50% increase in COVID-19 vaccine production

May. 4, 2021 at 8:10 a.m. ET by Ciara Linnane

Moderna to expand its manufacturing center in Massachusetts to 650,000 sq. ft vs. 300,000

May. 4, 2021 at 8:10 a.m. ET by Ciara Linnane

Moderna Inc. stock rises Monday, outperforms market

May. 3, 2021 at 4:31 p.m. ET by MarketWatch Automation

Denmark says it won't use J&J COVID vaccine due to blood-clotting concerns

May. 3, 2021 at 12:24 p.m. ET by Ciara Linnane

Barron's

Moderna Is Selling Up to 500 Million Covid Vaccine Doses to COVAX. What to Know.

May. 3, 2021 at 8:40 a.m. ET by Barron's

Barron's

Moderna Jumps, DraftKings Rises, and the Stock Market Looks Set for a Gain

May. 3, 2021 at 9:13 a.m. ET by Barron's

Stock Summer Swoon Coming?

May. 3, 2021 at 8:02 a.m. ET

Moderna to supply 500 million COVID-19 vaccine doses on behalf of COVAX

May. 3, 2021 at 6:12 a.m. ET by Tomi Kilgore

Moderna to supply up to 500 mln doses of its COVID-19 vaccine to Gavi on behalf of COVAX

May. 3, 2021 at 6:05 a.m. ET by Tomi Kilgore

These 20 stocks performed the best over the first 100 days of Biden’s presidency

Apr. 30, 2021 at 8:29 a.m. ET by Philip van Doorn

Moderna Inc. stock outperforms competitors on strong trading day

Apr. 30, 2021 at 4:31 p.m. ET by MarketWatch Automation

Moderna Inc. stock falls Thursday, underperforms market

Apr. 29, 2021 at 4:31 p.m. ET by MarketWatch Automation

Moderna in bid to double COVID-19 vaccine production to up to 3 billion doses in 2022

Apr. 29, 2021 at 3:51 p.m. ET

Barron's

Moderna in Bid to Double Covid-19 Vaccine Production to up to 3 Billion Doses in 2022

Apr. 29, 2021 at 11:13 a.m. ET by Barron's

Barron's

Biden’s Window for Passing His Bills is Narrowing

Apr. 29, 2021 at 11:59 a.m. ET

Moderna Inc. stock underperforms Wednesday when compared to competitors

Apr. 28, 2021 at 4:31 p.m. ET by MarketWatch Automation

Older adults 94% less likely to be hospitalized with COVID after receiving Pfizer or Moderna vaccines: CDC

Apr. 28, 2021 at 12:08 p.m. ET by Ciara Linnane

Moderna Inc. stock rises Tuesday, outperforms market

Apr. 27, 2021 at 4:31 p.m. ET by MarketWatch Automation

No Headlines Available

Other News
Press Releases

2 Revolutionary Stocks That Turned $200,000 Into $1,000,000

May. 4, 2021 at 6:12 a.m. ET on Motley Fool

Moderna Signs COVID-19 Vaccine Supply Deal With Gavi; Shares Gain 4%

May. 4, 2021 at 3:55 a.m. ET on TipRanks.com

Why Moderna Stock Jumped Today

May. 3, 2021 at 5:01 p.m. ET on Motley Fool

Wall Street Gears for a Hectic Earnings Week

May. 3, 2021 at 11:28 a.m. ET on Zacks.com

Markets Up to Start Another Busy Week

May. 3, 2021 at 10:31 a.m. ET on Zacks.com

Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?

May. 3, 2021 at 10:30 a.m. ET on Zacks.com

If You Have Ocugen Stock, Now’s the Time to Take Profits

May. 3, 2021 at 7:58 a.m. ET on InvestorPlace.com

The 2 Numbers I'll Be Looking for in Moderna's Earnings Report This Week

May. 3, 2021 at 6:00 a.m. ET on Motley Fool

Despite Covaxin News, Ocugen Stock Remains a Long-Shot for US Use

May. 3, 2021 at 6:00 a.m. ET on InvestorPlace.com

Analysts Offer Insights on Healthcare Companies: and Moderna (MRNA)

May. 3, 2021 at 5:03 a.m. ET on SmarterAnalyst

Moderna Just Made the Pfizer Vaccine's Biggest Weakness an Even Bigger One

May. 2, 2021 at 7:54 a.m. ET on Motley Fool

The Pfizer CEO Prediction That Could Mean Total COVID Market Dominance in 2022

May. 1, 2021 at 7:55 a.m. ET on Motley Fool

2 Top Biotech Stocks to Buy Right Now

Apr. 30, 2021 at 6:25 a.m. ET on Motley Fool

Could These 3 Brilliant mRNA Stocks Make You Millions?

Apr. 30, 2021 at 6:14 a.m. ET on Motley Fool

3 Stocks Poised for Huge Growth Over the Next Decade

Apr. 30, 2021 at 6:00 a.m. ET on Motley Fool

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Apr. 29, 2021 at 5:45 p.m. ET on Zacks.com

Moderna (MRNA) Reports Next Week: Wall Street Expects Earnings Growth

Apr. 29, 2021 at 5:00 p.m. ET on Zacks.com

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Apr. 29, 2021 at 4:17 p.m. ET on Zacks.com

10 of the Top Nasdaq Blue-Chip Stocks to Buy

Apr. 29, 2021 at 2:26 p.m. ET on InvestorPlace.com

7 Health-Focused ETFs To Buy Now For the Post-Covid Future

Apr. 29, 2021 at 2:10 p.m. ET on InvestorPlace.com

No Headlines Available

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.